OrthoPediatrics Secures Exclusive Deal for Bio-Integrative Fixation Tech in US Children's Hospitals
KIDS sits 29% above its 52-week low of $14.42.
Summary
OrthoPediatrics announced an exclusive distribution agreement with OSSIO, Inc. to provide bio-integrative, metal-free orthopedic fixation technology to U.S. children's hospitals. This "revolutionary" OSSIO*fiber*® technology is designed to be gradually replaced by the patient's bone, eliminating the need for secondary hardware removal surgeries common with metal implants. This strategic partnership expands OrthoPediatrics' product offering and market reach, addressing unmet pediatric needs and strengthening the company's long-term growth potential. This follows recent strong Q1 results and a new credit facility, indicating a continued focus on expanding its market presence and product portfolio.
At the time of this announcement, KIDS was trading at $18.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $472M. The 52-week trading range was $14.42 to $23.70. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.